Adelaide, Australia GPN Vaccines is pleased to announce that Dr Erin Brazel has been awarded a Junior Fellowship by the Passe & Williams Memorial Foundation. The prestigious fellowship secured by Dr Erin Brazel will support research on bacterial vaccines in a collaboration between GPN Vaccines and the...
Adelaide, Australia GPN Vaccines Ltd, a clinical-stage biotechnology company developing a Streptococcus pneumoniae vaccine to prevent life-threatening pneumonia, bacteraemia and meningitis, is pleased to announce positive safety and immunogenicity data from its Phase 1 trial of Gamma-PN, a non-adjuvanted whole cell-pneumococcal vaccine being investigated in adults aged...
Adelaide, Australia, 8th August 2023 GPN Vaccines is pleased to announce our recent success in the Australian Government’s National Industry PhD Program. The funding secured by the University of Adelaide’s Dr Erin Brazel, PhD student Carla Gallasch, and GPN Vaccines will support Carla to take part...
Adelaide, Australia, 7th August 2023 GPN Vaccines is pleased to announce that the Phase I clinical trial of Gamma-PN is now fully recruited. The Phase I clinical trial is assessing the safety, tolerability and immunogenicity of Gamma-PN – a novel broad-spectrum pneumococcal vaccine. One hundred and...
Adelaide, Australia- 22nd June 2023 - GPN Vaccines Ltd is pleased to announce dose escalation has been approved and dosing of the third, and final cohort of participants in its Phase 1 clinical trial of Gamma-PN has commenced. The Phase 1 clinical trial is assessing...
Adelaide, Australia, 30th March 2023 - GPN Vaccines Ltd is pleased to announce that dose escalation has been approved and dosing of the second cohort has commenced in its Phase 1 clinical trial of Gamma-PN vaccine in healthy volunteers. The Phase 1 clinical trial is assessing the...
GPN Vaccines was initially established with the goal of creating a vaccine capable of protecting children and adults against all serotypes of Streptococcus pneumoniae (the pneumococcus), a deadly pathogen responsible for killing up to two million people worldwide each year. Such a vaccine represents the...
Adelaide, Australia, 16th January 2023 GPN Vaccines Ltd is pleased to announce that the first participant has been dosed in its Phase 1 clinical trial of Gamma-PN vaccine in healthy volunteers. The Phase 1 clinical trial will assess the safety, tolerability and immunogenicity of Gamma-PN. One hundred...
Adelaide, Australia, 20th October 2022 - Professor Tim Hirst, GPN Vaccines’ Chairman and CEO, has been awarded Angel of the Year by Techboard, in recognition of his contribution to angel investment and his overall positive impact on the angel community. Tim commented, "I'm honoured to have been nominated by...